Parkinson’s Disease Treatment MarketGlobal Parkinson's Disease Treatment Market Analysis By Drug Class (Levodopa/Carbidopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Adenosine A2A Antagonists, Glutamate Antagonists, Cholinesterase Inhibitors, Others), By Disease Stage (Early-Stage, Advanced-Stage), By Route of Administration (Oral, Subcutaneous, Transdermal, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Published date: Oct 2025
Report ID: 160750
Number of Pages: 391
Format:

Fact Checked

Cite this Research

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Market Snapshot
  - 1.3. Market Overview
  - 1.4. Segment Overview
  - 1.5. Regional Overview
  - 1.6. Competitive Landscape
  - 1.7. Taxonomy
  - 1.8. Industry Voices
- 2. Global Market Overview
  - 2.1. Global Market Insights and Industry Overview
  - 2.2. Market Dynamics
    
    2.2.1. Drivers
    
    2.2.2. Restraints
    
    2.2.3. Opportunities
    
    2.2.4. Key Parkinson’s Disease Treatment Market Trends
  - 2.3. Disease Stage Landscape
  - 2.4. Regulatory Framework
  - 2.5. Sustainability and ESG (Environmental, Social, Governance)
  - 2.6. Opportunity Map Analysis
  - 2.7. Opportunity Orbits
  - 2.8. PESTLE Analysis
  - 2.9. PORTER’S Five Force Analysis
  - 2.10. Drivers & Restraints Impact Analysis
  - 2.11. Value Chain Analysis
    
    2.11.1. List of Raw Materials Suppliers
    
    2.11.2. List of Parkinson’s Disease Treatment Manufacturers
    
    2.11.3. List of Dealer/Distributors
  - 2.12. Regional Market Share and BPS Analysis
  - 2.13. Impact of Macro-economic Factors/Geopolitical Factors
- 3. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Segment, 2020-2034
  - 3.1. Key Findings
  - 3.2. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 3.3. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
    
    3.3.1. Levodopa/Carbidopa
    
    3.3.1.1. Insights
    
    3.3.1.2. Key Takeaways
    
    3.3.2. Dopamine Agonists
    
    3.3.2.1. Insights
    
    3.3.2.2. Key Takeaways
    
    3.3.3. MAO-B Inhibitors
    
    3.3.3.1. Insights
    
    3.3.3.2. Key Takeaways
    
    3.3.4. COMT Inhibitors
    
    3.3.4.1. Insights
    
    3.3.4.2. Key Takeaways
    
    3.3.5. Anticholinergics
    
    3.3.5.1. Insights
    
    3.3.5.2. Key Takeaways
    
    3.3.6. Adenosine A2A Antagonists
    
    3.3.6.1. Insights
    
    3.3.6.2. Key Takeaways
    
    3.3.7. Glutamate Antagonists
    
    3.3.7.1. Insights
    
    3.3.7.2. Key Takeaways
    
    3.3.8. Cholinesterase Inhibitors
    
    3.3.8.1. Insights
    
    3.3.8.2. Key Takeaways
    
    3.3.9. Others
    
    3.3.9.1. Insights
    
    3.3.9.2. Key Takeaways
  - 3.4. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 3.5. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
    
    3.5.1. Early-Stage
    
    3.5.1.1. Insights
    
    3.5.1.2. Key Takeaways
    
    3.5.2. Advanced-Stage
    
    3.5.2.1. Insights
    
    3.5.2.2. Key Takeaways
  - 3.6. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 3.7. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
    
    3.7.1. Oral
    
    3.7.1.1. Insights
    
    3.7.1.2. Key Takeaways
    
    3.7.2. Subcutaneous
    
    3.7.2.1. Insights
    
    3.7.2.2. Key Takeaways
    
    3.7.3. Transdermal
    
    3.7.3.1. Insights
    
    3.7.3.2. Key Takeaways
    
    3.7.4. Inhalation
    
    3.7.4.1. Insights
    
    3.7.4.2. Key Takeaways
  - 3.8. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 3.9. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
    
    3.9.1. Hospital Pharmacies
    
    3.9.1.1. Insights
    
    3.9.1.2. Key Takeaways
    
    3.9.2. Retail Pharmacies
    
    3.9.2.1. Insights
    
    3.9.2.2. Key Takeaways
    
    3.9.3. Online Pharmacies
    
    3.9.3.1. Insights
    
    3.9.3.2. Key Takeaways
- 4. Global Parkinson’s Disease Treatment Market Analysis and Forecast, By Region, 2020-2034
  - 4.1. Key Findings
  - 4.2. Global Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    
    4.2.1. North America
    
    4.2.1.1. Regional Insights
    
    4.2.2. Europe
    
    4.2.2.1. Regional Insights
    
    4.2.3. Asia Pacific
    
    4.2.3.1. Regional Insights
    
    4.2.4. Latin America
    
    4.2.4.1. Regional Insights
    
    4.2.5. Middle East & Africa
    
    4.2.5.1. Regional Insights
  - 4.3. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Region
- 5. North America Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
  - 5.1. Key Findings
  - 5.2. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 5.3. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - 5.4. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 5.5. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - 5.6. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 5.7. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - 5.8. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 5.9. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - 5.10. North America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 5.11. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
    
    5.11.1. The US
    
    5.11.2. Canada
- 6. Europe Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
  - 6.1. Key Findings
  - 6.2. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 6.3. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - 6.4. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 6.5. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - 6.6. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 6.7. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - 6.8. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 6.9. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - 6.10. Europe Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 6.11. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
    
    6.11.1. Germany
    
    6.11.2. The UK
    
    6.11.3. France
    
    6.11.4. Spain
    
    6.11.5. Italy
    
    6.11.6. Russia
    
    6.11.7. Netherland
    
    6.11.8. Rest of Europe
- 7. Asia Pacific Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
  - 7.1. Key Findings
  - 7.2. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 7.3. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - 7.4. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 7.5. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - 7.6. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 7.7. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - 7.8. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 7.9. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - 7.10. Asia Pacific Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 7.11. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
    
    7.11.1. China
    
    7.11.2. Japan
    
    7.11.3. South Korea
    
    7.11.4. India
    
    7.11.5. Australia
    
    7.11.6. New Zealand
    
    7.11.7. Singapore
    
    7.11.8. Thailand
    
    7.11.9. Vietnam
    
    7.11.10. Rest of Asia Pacific
- 8. Latin America Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
  - 8.1. Key Findings
  - 8.2. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 8.3. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - 8.4. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 8.5. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - 8.6. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 8.7. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - 8.8. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 8.9. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - 8.10. Latin America Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 8.11. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
    
    8.11.1. Brazil
    
    8.11.2. Mexico
    
    8.11.3. Rest of Latin America
- 9. Middle East & Africa Parkinson’s Disease Treatment Market Analysis and Forecast, 2020-2034
  - 9.1. Key Findings
  - 9.2. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 9.3. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - 9.4. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Stage, 2020-2034
  - 9.5. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - 9.6. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 9.7. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - 9.8. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  - 9.9. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - 9.10. Middle East & Africa Parkinson’s Disease Treatment Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 9.11. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
    
    9.11.1. South Africa
    
    9.11.2. Saudi Arabia
    
    9.11.3. UAE
    
    9.11.4. Rest of Middle East & Africa
- 10. Competitive Landscape & Company Profiles
  - 10.1. Market Competition Scenario Analysis, By Company
    
    10.1.1. Key Takeaways
  - 10.2. Overview of Major Market Players
  - 10.3. Competitor Landscape
  - 10.4. Strategic Mapping
  - 10.5. Company Life Cycle Analysis
  - 10.6. Company Market Share Analysis
  - 10.7. Company Profiles
    
    10.7.1. AbbVie Inc.
    
    10.7.1.1. Company Details
    
    10.7.1.2. Business Overview
    
    10.7.1.3. Product Portfolio
    
    10.7.1.4. Financial Insights
    
    10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.1.6. SWOT Analysis
    
    10.7.1.7. Geographic Footprint
    
    10.7.2. Amgen Inc.
    
    10.7.2.1. Company Details
    
    10.7.2.2. Business Overview
    
    10.7.2.3. Product Portfolio
    
    10.7.2.4. Financial Insights
    
    10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.2.6. SWOT Analysis
    
    10.7.2.7. Geographic Footprint
    
    10.7.3. Teva Pharmaceutical Industries Ltd.
    
    10.7.3.1. Company Details
    
    10.7.3.2. Business Overview
    
    10.7.3.3. Product Portfolio
    
    10.7.3.4. Financial Insights
    
    10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.3.6. SWOT Analysis
    
    10.7.3.7. Geographic Footprint
    
    10.7.4. GlaxoSmithKline plc
    
    10.7.4.1. Company Details
    
    10.7.4.2. Business Overview
    
    10.7.4.3. Product Portfolio
    
    10.7.4.4. Financial Insights
    
    10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.4.6. SWOT Analysis
    
    10.7.4.7. Geographic Footprint
    
    10.7.5. Merck & Co., Inc.
    
    10.7.5.1. Company Details
    
    10.7.5.2. Business Overview
    
    10.7.5.3. Product Portfolio
    
    10.7.5.4. Financial Insights
    
    10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.5.6. SWOT Analysis
    
    10.7.5.7. Geographic Footprint
    
    10.7.6. Pfizer Inc.
    
    10.7.6.1. Company Details
    
    10.7.6.2. Business Overview
    
    10.7.6.3. Product Portfolio
    
    10.7.6.4. Financial Insights
    
    10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.6.6. SWOT Analysis
    
    10.7.6.7. Geographic Footprint
    
    10.7.7. UCB S.A.
    
    10.7.7.1. Company Details
    
    10.7.7.2. Business Overview
    
    10.7.7.3. Product Portfolio
    
    10.7.7.4. Financial Insights
    
    10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.7.6. SWOT Analysis
    
    10.7.7.7. Geographic Footprint
    
    10.7.8. Lundbeck A/S
    
    10.7.8.1. Company Details
    
    10.7.8.2. Business Overview
    
    10.7.8.3. Product Portfolio
    
    10.7.8.4. Financial Insights
    
    10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.8.6. SWOT Analysis
    
    10.7.8.7. Geographic Footprint
    
    10.7.9. Boehringer Ingelheim GmbH
    
    10.7.9.1. Company Details
    
    10.7.9.2. Business Overview
    
    10.7.9.3. Product Portfolio
    
    10.7.9.4. Financial Insights
    
    10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.9.6. SWOT Analysis
    
    10.7.9.7. Geographic Footprint
    
    10.7.10. Sanofi S.A.
    
    10.7.10.1. Company Details
    
    10.7.10.2. Business Overview
    
    10.7.10.3. Product Portfolio
    
    10.7.10.4. Financial Insights
    
    10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.10.6. SWOT Analysis
    
    10.7.10.7. Geographic Footprint
    
    10.7.11. Sunovion Pharmaceuticals Inc.
    
    10.7.11.1. Company Details
    
    10.7.11.2. Business Overview
    
    10.7.11.3. Product Portfolio
    
    10.7.11.4. Financial Insights
    
    10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.11.6. SWOT Analysis
    
    10.7.11.7. Geographic Footprint
    
    10.7.12. Mylan N.V.
    
    10.7.12.1. Company Details
    
    10.7.12.2. Business Overview
    
    10.7.12.3. Product Portfolio
    
    10.7.12.4. Financial Insights
    
    10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.12.6. SWOT Analysis
    
    10.7.12.7. Geographic Footprint
    
    10.7.13. Roche Holding AG
    
    10.7.13.1. Company Details
    
    10.7.13.2. Business Overview
    
    10.7.13.3. Product Portfolio
    
    10.7.13.4. Financial Insights
    
    10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.13.6. SWOT Analysis
    
    10.7.13.7. Geographic Footprint
- 11. Methodology and Data Source
  - 11.1. Methodology/Research Approach
  - 11.2. Market Size Estimation
  - 11.3. Market Breakdown and Data Triangulation
  - 11.4. Data Source
  - 11.5. Secondary Sources
  - 11.6. Primary Sources
  - 11.7. Appendix
  - 11.8. Disclaimer
- List of Tables
  - Table 1. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 2. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 3. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 4. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 5. Global Parkinson’s Disease Treatment Market Value (US$ Mn), By Region, 2020-2034
  - Table 6. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 7. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 8. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 9. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 10. North America Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
  - Table 11. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 12. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 13. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 14. The US Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 15. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 16. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 17. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 18. Canada Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 19. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 20. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 21. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 22. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 23. Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
  - Table 24. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 25. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 26. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 27. Germany Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 28. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 29. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 30. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 31. The UK Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 32. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 33. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 34. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 35. France Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 36. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 37. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 38. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 39. Spain Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 40. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 41. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 42. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 43. Italy Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 44. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 45. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 46. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 47. Russia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 48. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 49. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 50. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 51. Netherland Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 52. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 53. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 54. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 55. Rest of Europe Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 56. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 57. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 58. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 59. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 60. Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
  - Table 61. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 62. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 63. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 64. China Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 65. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 66. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 67. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 68. India Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 69. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 70. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 71. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 72. Japan Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 73. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 74. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 75. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 76. South Korea Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 77. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 78. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 79. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 80. Australia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 81. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 82. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 83. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 84. New Zealand Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 85. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 86. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 87. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 88. Singapore Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 89. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 90. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 91. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 92. Thailand Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 93. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 94. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 95. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 96. Vietnam Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 97. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 98. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 99. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 100. Rest of Asia Pacific Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 101. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 102. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 103. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 104. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 105. Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
  - Table 106. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 107. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 108. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 109. Brazil Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 110. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 111. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 112. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 113. Mexico Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 114. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 115. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 116. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 117. Rest of Latin America Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 118. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 119. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 120. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 121. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 122. Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Country, 2020-2034
  - Table 123. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 124. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 125. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 126. South Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 127. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 128. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 129. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 130. Saudi Arabia Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 131. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 132. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 133. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 134. UAE Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
  - Table 135. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 136. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Disease Stage, 2020-2034
  - Table 137. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 138. Rest of Middle East & Africa Parkinson’s Disease Treatment Market Value (US$ Mn), By Distribution Channel, 2020-2034
- List of Figures
  - Figure 1. Global Parkinson’s Disease Treatment Market Snapshot: Market Value (US$ Mn), 2020-2034
  - Figure 2. Opportunity Map
  - Figure 3. Opportunity Orbit
  - Figure 4. Regional Market Share and BPS Analysis in Parkinson’s Disease Treatment Market
  - Figure 5. Global Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 6. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 7. Global Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 8. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 9. Global Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 10. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 11. Global Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 12. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 13. Global Parkinson’s Disease Treatment Market Analysis, By Region, 2020, 2024 and 2034
  - Figure 14. Global Parkinson’s Disease Treatment Market Attractiveness Analysis, By Region
  - Figure 15. North America Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 16. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 17. North America Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
  - Figure 18. North America Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
  - Figure 19. North America Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
  - Figure 20. North America Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
  - Figure 21. North America Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
  - Figure 22. North America Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
  - Figure 23. North America Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
  - Figure 24. North America Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
  - Figure 25. North America Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
  - Figure 26. North America Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 27. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 28. North America Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
  - Figure 29. North America Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
  - Figure 30. North America Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 31. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 32. North America Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
  - Figure 33. North America Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
  - Figure 34. North America Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
  - Figure 35. North America Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
  - Figure 36. North America Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 37. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 38. North America Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
  - Figure 39. North America Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
  - Figure 40. North America Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
  - Figure 41. North America Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 42. North America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
  - Figure 43. Europe Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 44. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 45. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
  - Figure 46. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
  - Figure 47. Europe Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
  - Figure 48. Europe Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
  - Figure 49. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
  - Figure 50. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
  - Figure 51. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
  - Figure 52. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
  - Figure 53. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
  - Figure 54. Europe Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 55. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 56. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
  - Figure 57. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
  - Figure 58. Europe Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 59. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 60. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
  - Figure 61. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
  - Figure 62. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
  - Figure 63. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
  - Figure 64. Europe Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 65. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 66. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
  - Figure 67. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
  - Figure 68. Europe Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
  - Figure 69. Europe Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 70. Europe Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
  - Figure 71. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 72. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 73. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
  - Figure 74. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
  - Figure 75. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
  - Figure 76. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
  - Figure 77. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
  - Figure 78. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
  - Figure 79. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
  - Figure 80. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
  - Figure 81. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
  - Figure 82. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 83. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 84. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
  - Figure 85. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
  - Figure 86. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 87. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 88. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
  - Figure 89. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
  - Figure 90. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
  - Figure 91. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
  - Figure 92. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 93. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 94. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
  - Figure 95. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
  - Figure 96. Asia Pacific Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
  - Figure 97. Asia Pacific Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 98. Asia Pacific Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
  - Figure 99. Latin America Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 100. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 101. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
  - Figure 102. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
  - Figure 103. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
  - Figure 104. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
  - Figure 105. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
  - Figure 106. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
  - Figure 107. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
  - Figure 108. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
  - Figure 109. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
  - Figure 110. Latin America Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 111. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 112. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
  - Figure 113. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
  - Figure 114. Latin America Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 115. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 116. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
  - Figure 117. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
  - Figure 118. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
  - Figure 119. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
  - Figure 120. Latin America Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 121. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 122. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
  - Figure 123. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
  - Figure 124. Latin America Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
  - Figure 125. Latin America Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 126. Latin America Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
  - Figure 127. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 128. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Drug Class
  - Figure 129. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Levodopa/Carbidopa, 2020-2034
  - Figure 130. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Dopamine Agonists, 2020-2034
  - Figure 131. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by MAO-B Inhibitors, 2020-2034
  - Figure 132. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by COMT Inhibitors, 2020-2034
  - Figure 133. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Anticholinergics, 2020-2034
  - Figure 134. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Adenosine A2A Antagonists, 2020-2034
  - Figure 135. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Glutamate Antagonists, 2020-2034
  - Figure 136. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Cholinesterase Inhibitors, 2020-2034
  - Figure 137. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Others, 2020-2034
  - Figure 138. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Disease Stage, 2020, 2024 and 2034
  - Figure 139. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Disease Stage
  - Figure 140. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Early-Stage, 2020-2034
  - Figure 141. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Advanced-Stage, 2020-2034
  - Figure 142. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Disease Stage 3, 2020-2034
  - Figure 143. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 144. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Route of Administration
  - Figure 145. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Oral, 2020-2034
  - Figure 146. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Subcutaneous, 2020-2034
  - Figure 147. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Transdermal, 2020-2034
  - Figure 148. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Inhalation, 2020-2034
  - Figure 149. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Distribution Channel, 2020, 2024 and 2034
  - Figure 150. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Distribution Channel
  - Figure 151. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Hospital Pharmacies, 2020-2034
  - Figure 152. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Retail Pharmacies, 2020-2034
  - Figure 153. Middle East & Africa Parkinson’s Disease Treatment Market (US$ Mn), by Online Pharmacies, 2020-2034
  - Figure 154. Middle East & Africa Parkinson’s Disease Treatment Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 155. Middle East & Africa Parkinson’s Disease Treatment Market Attractiveness Analysis, By Country
- AbbVie Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Pfizer Inc.
- UCB S.A.
- Lundbeck A/S
- Boehringer Ingelheim GmbH
- Sanofi S.A.
- Sunovion Pharmaceuticals Inc.
- Mylan N.V.
- Roche Holding AG
- Other key players